Summit Corporation plc Antibiotic Eligible For Fast Track

The Oxford based drugmaker Summit Corporation (LSE: SUMM) announced today that the antibiotic SMT19969 has been designated by the US regulator as a Qualified Infectious Disease Product (‘QIDP’).

AstraZenecaThe drug, which treats C. difficile infection, is therefore eligible for priority review and fast track status under the Generating Antibiotics Incentives Now Act.

The QIDP designation also qualifies SMT19969 for five additional years of marketing exclusivity.

The chief executive, Glyn Edwards, said:

“This status recognises the serious healthcare threat posed by pathogens such as C. difficile and it will confer a number of advantages that will accelerate the development of this promising and differentiated antibiotic with the potential to treat initial CDI and reduce the high rates of disease recurrence, the major clinical issue.”

Summit shares trade at 17 times forecast earnings which is a more punchy valuation than its blue-chip sector peers. The decision to ‘buy’ would depend on further investigation into the drugs pipeline.

But if you're interested to find out the Motley Fool's preferred play on the pharmaceutical sector, then I suggest you read "The Fool's Five Shares To Retire On", which features features in depth reports on five 'must own' stocks for 2014 and beyond.

For your free copy simply click here now.

Mark does not own shares in Summit Corp.